Systemic inflammation and risk stratification in pheochromocytoma: Insights from PASS components, TNM stage, and the tumor immune microenvironment
Introduction: The Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and Tumor–Node–Metastasis (TNM) staging capture histopathological and anatomical risk features in adrenal pheochromocytoma, but do not incorporate systemic inflammation.
Objectives: To investigate the associations of preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with individual PASS components and American Joint Committee on Cancer TNM stage in adrenal pheochromocytoma.
Methods: We retrospectively screened 62 patients; after predefined exclusions, 55 patients with adrenal pheochromocytoma were included. Clinical characteristics, tumor size, urinary metanephrine and normetanephrine levels, PASS components, TNM stage, and preoperative blood counts were recorded. Associations of NLR and PLR with PASS components were assessed using univariate logistic regression, with Benjamini–Hochberg correction across the 12 component-level analyses. NLR and PLR were also compared between Stage I/II and Stage III/IV disease.
Results: After Benjamini–Hochberg correction, associations of NLR with vascular invasion and high cellularity were attenuated, whereas those with capsular invasion, large nests or diffuse growth, tumor necrosis, atypical mitosis, and mitotic activity > 3/10 high-power fields remained significant. NLR was higher in Stage III/IV than Stage I/II disease (median: 3.85; range: 2.17–6.73 vs. median: 2.59; range: 1.52–5.48, p = 0.019). PLR was associated with PASS ≥ 6 in the unadjusted analysis but not with individual PASS components and did not differ by stage.
Conclusion: Higher preoperative NLR was associated with selected PASS components and Stage III/IV disease in adrenal pheochromocytoma. These exploratory findings require validation in larger multicenter cohorts and should not be interpreted as evidence of independent prognostic value.
- Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022;33(1):90-114. doi: 10.1007/s12022-022-09704-6
- Clarke MR, Weyant RJ, Watson CG, Carty SE. Prognostic Markers in Pheochromocytoma. Hum Pathol. 1998;29(5):522-526. doi: 10.1016/S0046-8177(98)90070-3
- Medley IL, Keiser HR, Steinberg SM, Lack EE. Histopathology of Benign Versus Malignant Sympathoadrenal Paragangliomas: Clinicopathologic Study of 120 Cases Including Unusual Histologic Features. Hum Pathol. 1990;21(11):1168-1180. doi: 10.1016/0046-8177(90)90155-X
- Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol. 2021;23(10):1995-2019. doi: 10.1007/s12094-021-02622-9
- Pierre C, Agopiantz M, Brunaud L, et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas. Virchows Arch. 2019;474(6):721-734. doi: 10.1007/s00428-019-02553-5
- Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21(3):405-414. doi: 10.1530/ERC-13-0494
- Wu D, Tischler AS, Lloyd RV, et al. Observer Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol. 2009;33(4):599-608. doi: 10.1097/PAS.0b013e318190d3e8
- Wachtel H, Hutchens T, Baraban E, et al. Predicting metastatic potential in pheochromocytoma and paraganglioma: A comparison of PASS and GAPP scoring systems. J Clin Endocrinol Metab. 2020;105(12):e4661-e4670. doi: 10.1210/clinem/dgaa608
- de Bresser CJM, de Krijger RR. The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease. Endocr Pathol. 2024;35(4):279-292. doi: 10.1007/s12022-024-09830-3
- Jimenez C, Ma J, Gonzalez AR, et al. TNM Staging and Overall Survival in Patients with Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab. 2023;108(5):1132-1142. doi: 10.1210/clinem/dgac677
- Milinkovic M, Soldatovic I, Zivaljevic V, et al. Comprehensive Investigation of Angiogenesis, PASS Score and Immunohistochemical Factors in Risk Assessment of Malignancy for Paraganglioma and Pheochromocytoma. Diagnostics. 2024;14(8):849. doi: 10.3390/diagnostics14080849
- Ruf B, Greten TF, Korangy F. Innate lymphoid cells and innate-like T cells in cancer — at the crossroads of innate and adaptive immunity. Nat Rev Cancer. 2023;23(6):351-371. doi: 10.1038/s41568-023-00562-w
- Martinelli S, Amore F, Canu L, Maggi M, Rapizzi E. Tumour microenvironment in pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne). 2023;14:1137456. doi: 10.3389/fendo.2023.1137456
- Beis D, Von Känel R, Heimgartner N, et al. The Role of Norepinephrine and α-Adrenergic Receptors in Acute Stress-Induced Changes in Granulocytes and Monocytes. Psychosom Med. 2018;80(7):649-658. doi: 10.1097/PSY.0000000000000620
- Zhong X, Su TW, Yang Y, et al. Platelet-Lymphocyte and Neutrophil-Lymphocyte Ratios Are Prognostic Markers for Pheochromocytomas and Paragangliomas. J Clin Endocrinol Metab. 2023;108(9):2230-2239. doi: 10.1210/clinem/dgad149
- Çavdar Ü, Kalender DSY, Yüksel BD, et al. Prognostic Significance of Preoperative NLR or PLR and PASS Score Combinations in Pheochromocytoma and Paraganglioma. Clin Endocrinol (Oxf). 2025;102(3):362-368. doi: 10.1111/cen.15192
- Thompson LDR. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases. Am J Surg Pathol. 2002;26(5):551-566. doi: 10.1097/00000478-200205000-00002
- Thompson LDR, Gill AJ, Asa SL, et al. Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Hum Pathol. 2021;110:83-97. doi: 10.1016/j.humpath.2020.04.012
- Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812-830.e14. doi: 10.1016/j.immuni.2018.03.023
- Marques P, De Vries F, Dekkers OM, Korbonits M, Biermasz NR, Pereira AM. Serum Inflammation-based Scores in Endocrine Tumors. J Clin Endocrinol Metab. 2021;106(10):e3796-e3819. doi: 10.1210/clinem/dgab238
- Carrión-Barberà I, Lood C. Performance of the neutrophil-to-lymphocyte ratio as a prognostic tool for survival in solid cancers. Front Oncol. 2025;15:1616477. doi: 10.3389/fonc.2025.1616477
- Tufton N, Hearnden RJ, Berney DM, et al. The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas. Endocr Relat Cancer. 2022;29(11):589-598. doi: 10.1530/ERC-22-0020
- Uher O, Vanova KH, Taïeb D, et al. The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives. Endocr Rev. 2024;45(4):521-552. doi: 10.1210/endrev/bnae005
- Calsina B, Piñeiro-Yáñez E, Martínez-Montes ÁM, et al. Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma. Nat Commun. 2023;14(1):1122. doi: 10.1038/s41467-023-36769-6
- Stenman A, Zedenius J, Juhlin CC. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up. Surgery. 2019;166(5):901-906. doi: 10.1016/j.surg.2019.04.030
- Abdel-Rahman O. Assessment of the AJCC staging system of pheochromocytomas/paragangliomas. Endocrine. 2022;75(1):239-243. doi: 10.1007/s12020-021-02854-3
- Torresan F, Beber A, Schiavone D, et al. Long-Term Outcomes after Surgery for Pheochromocytoma and Sympathetic Paraganglioma. Cancers (Basel). 2023;15(11):2890. doi: 10.3390/cancers15112890
- Platini H, Ferdinand E, Kohar K, et al. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2022;58(8):1069. doi: 10.3390/medicina58081069
- Guo W, Lu X, Liu Q, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals. Cancer Med. 2019;8(9):4135-4148. doi: 10.1002/cam4.2281
- Shi M, Zhao W, Zhou F, et al. Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma. Transl Lung Cancer Res. 2020;9(1):45-54. doi: 10.21037/tlcr.2020.01.17
- Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99. doi: 10.3322/caac.21388
